ADBiotech Co., Ltd. (KOSDAQ:179530)

ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 48.02 billion. The enterprise value is 47.53 billion.

Market Cap	48.02B
Enterprise Value	47.53B

Important Dates

The next estimated earnings date is Friday, March 20, 2026.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 16.36 million shares outstanding. The number of shares has increased by 17.13% in one year.

Current Share Class	16.36M
Shares Outstanding	16.36M
Shares Change (YoY)	+17.13%
Shares Change (QoQ)	+9.46%
Owned by Insiders (%)	15.52%
Owned by Institutions (%)	9.02%
Float	5.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.30
PB Ratio	26.03
P/TBV Ratio	27.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.31
EV / Sales	3.26
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.58

Financial Position

The company has a current ratio of 0.67, with a Debt / Equity ratio of 4.17.

Current Ratio	0.67
Quick Ratio	0.45
Debt / Equity	4.17
Debt / EBITDA	n/a
Debt / FCF	-3.17
Interest Coverage	-3.42

Financial Efficiency

Return on equity (ROE) is -444.50% and return on invested capital (ROIC) is -23.65%.

Return on Equity (ROE)	-444.50%
Return on Assets (ROA)	-11.65%
Return on Invested Capital (ROIC)	-23.65%
Return on Capital Employed (ROCE)	-80.06%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.59
Inventory Turnover	3.74

Taxes

Income Tax	-192.54M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +20.29% in the last 52 weeks. The beta is 1.41, so ADBiotech's price volatility has been higher than the market average.

Beta (5Y)	1.41
52-Week Price Change	+20.29%
50-Day Moving Average	3,390.90
200-Day Moving Average	2,778.90
Relative Strength Index (RSI)	40.33
Average Volume (20 Days)	170,548

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 14.57 billion and -11.02 billion in losses. Loss per share was -1,029.38.

Revenue	14.57B
Gross Profit	5.57B
Operating Income	-4.57B
Pretax Income	-11.40B
Net Income	-11.02B
EBITDA	-3.56B
EBIT	-4.57B
Loss Per Share	-1,029.38

Balance Sheet

The company has 8.23 billion in cash and 7.70 billion in debt, giving a net cash position of 530.47 million or 32.42 per share.

Cash & Cash Equivalents	8.23B
Total Debt	7.70B
Net Cash	530.47M
Net Cash Per Share	32.42
Equity (Book Value)	1.85B
Book Value Per Share	142.18
Working Capital	-7.09B

Cash Flow

In the last 12 months, operating cash flow was -2.19 billion and capital expenditures -241.76 million, giving a free cash flow of -2.43 billion.

Operating Cash Flow	-2.19B
Capital Expenditures	-241.76M
Free Cash Flow	-2.43B
FCF Per Share	-148.37

Margins

Gross margin is 38.24%, with operating and profit margins of -31.37% and -75.63%.

Gross Margin	38.24%
Operating Margin	-31.37%
Pretax Margin	-78.27%
Profit Margin	-75.63%
EBITDA Margin	-24.45%
EBIT Margin	-31.37%
FCF Margin	n/a

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.13%
Shareholder Yield	-17.13%
Earnings Yield	-22.94%
FCF Yield	-5.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -1.44 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.44
Piotroski F-Score	5